Next Article in Journal
Is Bilateral Facial Paralysis an Indicator of Respiratory Outcome in Guillain–Barré Syndrome?
Previous Article in Journal
The Effect of Thyroid Stimulating Hormone Level Within the Reference Range on In-Hospital and Short-Term Prognosis in Acute Coronary Syndrome Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 55
Issue 5
10.3390/medicina55050176
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab

by
Sijan Basnet
1,*,
Rashmi Dhital
1 and
Biswaraj Tharu
2
1
Department of Internal Medicine, Reading Hospital, 420 S Fifth Avenue, West Reading, PA 19611, USA
2
Department of Internal Medicine, Trumbull Regional Medical Center, 1350 E Market St, Warren, OH 44483, USA
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(5), 176; https://doi.org/10.3390/medicina55050176
Submission received: 15 January 2019 / Revised: 5 February 2019 / Accepted: 14 May 2019 / Published: 21 May 2019
Browse Figure
Versions Notes

Abstract

Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment.
Keywords: pembrolizumab; acute kidney injury; programmed cell death 1 inhibitor; non-small cell lung cancer pembrolizumab; acute kidney injury; programmed cell death 1 inhibitor; non-small cell lung cancer

Share and Cite

MDPI and ACS Style

Basnet, S.; Dhital, R.; Tharu, B. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. Medicina 2019, 55, 176. https://doi.org/10.3390/medicina55050176

AMA Style

Basnet S, Dhital R, Tharu B. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. Medicina. 2019; 55(5):176. https://doi.org/10.3390/medicina55050176

Chicago/Turabian Style

Basnet, Sijan, Rashmi Dhital, and Biswaraj Tharu. 2019. "Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab" Medicina 55, no. 5: 176. https://doi.org/10.3390/medicina55050176

APA Style

Basnet, S., Dhital, R., & Tharu, B. (2019). Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. Medicina, 55(5), 176. https://doi.org/10.3390/medicina55050176

Article Metrics

Back to TopTop